OPKO Health Inc (OPK)

6.99
NASDAQ : Health Care
Prev Close 6.69
Day Low/High 6.71 / 6.99
52 Wk Low/High 5.99 / 12.15
Avg Volume 4.09M
Exchange NASDAQ
Shares Outstanding 559.39M
Market Cap 3.74B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OPKO'S GeneDx Extends Relationship With University Of California Health For Genetic And Molecular Testing

OPKO Helps Expand UC Health's leadership at the forefront of precision medicine

Xenetic Biosciences Receives Program Update From Partner Shire's Phase 1/2 Study Evaluating SHP656 In Development As A Long-acting Treatment For Hemophilia A

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health's 4Kscore® Test Highlighted In Podium Presentation At 112th American Urological Association Annual Meeting

Prospective study conducted at Veteran Affairs hospitals confirms 4Kscore accurately predicts aggressive prostate cancer

Insiders Are Loading Up on GE, Twilio & More

Insiders Are Loading Up on GE, Twilio & More

Insiders at General Electric, Twilio and three other companies have been snapping up shares of their own stock lately.

Xenetic Biosciences Reports 2017 First Quarter Financial Results And Provides Business Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

CORRECTION -- OPKO Health Inc.

Xenetic Biosciences To Host 2017 First Quarter Update Conference Call

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Presents Case Study Of PolyXen™ Platform Technology At The 13th Annual Protein Engineering Summit (PEGS) Boston

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences' PolyXen™ Platform Technology Accepted For Poster Presentation At The 13th Annual Protein Engineering Summit (PEGS) Boston

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Expands Executive Management Team With Appointment Of James F. Parslow, MBA, CPA As Chief Financial Officer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round

Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round

Jim Cramer is bullish on Constellation Brands, Cypress Semiconductor and Philip Morris International.

Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)

Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)

Brouhaha over GOP-led health-care deal is not really threatening the Republic. But you should have an investment plan in place.

4 Stocks Under $10 Setting Up to Break Out

4 Stocks Under $10 Setting Up to Break Out

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

OPKO Subsidiary GenPath Women's Health Announces The Availability Of ClariTest™

Non-invasive prenatal test that harnesses the power of massively parallel sequencing to screen for fetal chromosomal abnormalities

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Opko Health, FireEye, KBR: 'Mad Money' Lightning Round

Opko Health, FireEye, KBR: 'Mad Money' Lightning Round

Jim Cramer says Opko Health has lost its mojo; but he's bullish on KBR for its cash stash.

Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)

Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)

Growth is not only about the occupant of the Oval Office, say Jim Cramer. This is a genuine bull market, and it's about how you invest.